Advances in hydrogel technology have unlocked unique and valuable capabilities that are
being applied to a diverse set of translational applications. Hydrogels perform functions …

Tumor-promoting inflammation and the avoidance of immune destruction are hallmarks of
cancer. While innate immune cells, such as neutrophils, monocytes, and macrophages, are …

Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies
(mAbs) can unleash antitumor functions of T cells but is associated with variable response …

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily.
Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

Chimeric antigen receptor (CAR) T cells provide great efficacy in B cell malignancies.
However, improved CAR T cell therapies are still needed. Here, we engineered tumor …

Interactions between the crystallizable fragment (Fc) domain of antibodies and a plethora of
cellular Fc receptors (FcRs) or soluble proteins form a critical link between humoral and …

Therapeutic use of agonistic anti-CD40 antibodies is a potentially powerful approach for
activation of the immune response to eradicate tumors. However, the translation of this …

Intravesical immunotherapy using Bacille Calmette-Guérin (BCG) attenuated bacteria
delivered transurethrally to the bladder has been the standard of care for patients with high …